NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Rating of “Moderate Buy” from Analysts

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) have been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $38.25.

A number of analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of NRx Pharmaceuticals in a research report on Monday, April 27th. Zacks Research raised NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Ascendiant Capital Markets raised their target price on NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. BTIG Research reissued a “buy” rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a research report on Tuesday, March 24th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $34.00 price target on shares of NRx Pharmaceuticals in a research report on Tuesday, May 5th.

NRx Pharmaceuticals Price Performance

NASDAQ:NRXP opened at $3.56 on Friday. The business has a fifty day simple moving average of $3.47 and a two-hundred day simple moving average of $2.59. NRx Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $5.05. The company has a market capitalization of $128.98 million, a P/E ratio of -3.27 and a beta of 2.14.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its earnings results on Friday, May 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $19.43 million. As a group, analysts anticipate that NRx Pharmaceuticals will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several hedge funds have recently made changes to their positions in NRXP. Geode Capital Management LLC grew its position in shares of NRx Pharmaceuticals by 27.9% in the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after purchasing an additional 37,598 shares in the last quarter. Vanguard Group Inc. grew its position in shares of NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares in the last quarter. Two Sigma Investments LP grew its position in shares of NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares in the last quarter. Anson Funds Management LP grew its position in shares of NRx Pharmaceuticals by 26.2% in the third quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock valued at $6,683,000 after purchasing an additional 420,129 shares in the last quarter. Finally, One Wealth Management Investment & Advisory Services LLC grew its position in shares of NRx Pharmaceuticals by 35.3% in the fourth quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock valued at $103,000 after purchasing an additional 9,882 shares in the last quarter. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.